secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0000950103-21-017524
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River previews 2022: low-double-digit organic revenue growth, margin expansion, 9% capex
--------------------------------------------------------------------------------

- Expects low-double-digit organic revenue growth in 2022 driven by sustained robust demand.
- Non-GAAP operating margin improvement targeted towards ~22.5% by 2024.
- Staffing levels increased ahead of plan; compensation expected to be headwind in 2022.
- Capital expenditure guided at ~9% of total revenue in 2022, mainly for Safety Assessment capacity.
- Outlook presented at Credit Suisse 30th Annual Healthcare Conference on Nov 9, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/0000950103-21-017524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000095010321017524/dp161446_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-21-017524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer